Table of Contents Author Guidelines Submit a Manuscript
Cardiology Research and Practice
Volume 2012, Article ID 135819, 5 pages
http://dx.doi.org/10.1155/2012/135819
Clinical Study

The Experience of a Multidisciplinary Clinic in the Management of Early-Stage Breast Cancer Patients Receiving Trastuzumab Therapy: An Observational Study

1Division of Medical Oncology, Department of Medicine, University of Ottawa, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada K1H 8L6
2Department of Pharmacy, The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada K1H 8L6
3The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada K1H 8L6
4Division of Cardiology, Department of Medicine, University of Ottawa, The Ottawa Hospital, Ottawa, ON, Canada K1H 8L6

Received 14 May 2012; Revised 24 July 2012; Accepted 25 July 2012

Academic Editor: Syed Wamique Yusuf

Copyright © 2012 Susan Dent et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Jardines, S. Goyal, P. Fisher et al., Breast Cancer Overview: Risk Factors, Screening, Genetic Testing, and Prevention, Cancer Management Handbook, 14th edition, 2011.
  2. Early Breast Cancer Trialists' Collaborative Group, “Polychemotherapy for early breast cancer: an overview of the randomised trials,” The Lancet, vol. 352, no. 9132, pp. 930–942, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. D. J. Slamon, G. M. Clark, S. G. Wong et al., “Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene,” Science, vol. 235, no. 4785, pp. 177–182, 1987. View at Google Scholar · View at Scopus
  4. A. M. Feldman, B. H. Lorell, and S. E. Reis, “Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity,” Circulation, vol. 102, no. 3, pp. 272–274, 2000. View at Google Scholar · View at Scopus
  5. E. A. Perez, E. H. Romond, V. J. Suman et al., “Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2- positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31,” Journal of Clinical Oncology, vol. 29, no. 25, pp. 3366–3373, 2011. View at Google Scholar
  6. L. Gianni, U. Dafni, R. D. Gelber et al., “Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial,” The Lancet Oncology, vol. 12, no. 3, pp. 236–244, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. N. J. Robert, W. Eiermann, T. Pienkowski et al., “BCIRG 006: docetaxel and trastuzumab-based regimens improve DFS and OS over AC-T in node positive and high risk node negative HER2 positive early breast cancer patients: quality of life (QOL) at 36 months follow-up,” Journal of Clinical Oncology, vol. 23, article 556, 2007. View at Google Scholar
  8. E. H. Romond, E. A. Perez, J. Bryant et al., “Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer (Joint Report Of The NSABP B-31 And NCCTG N9831 Trials),” The New England Journal of Medicine, vol. 353, pp. 1673–1684, 2005. View at Google Scholar
  9. I. Smith, M. Procter, R. D. Gelber et al., “2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial,” The Lancet, vol. 369, pp. 29–36, 2007. View at Publisher · View at Google Scholar
  10. L. Moja, C. Brambilla, A. Compagnoni et al., “Trastuzumab containing regimens for early breast cancer,” Cochrane Database of Systematic Reviews, vol. 4, Article ID CD006243, 2012. View at Google Scholar
  11. S. F. Dent, L. A. Vandermeer, J. N. Spaans et al., “Adjuvant trastuzumab in early stage breast cancer: is cardiac dysfunction clinically significant,” Journal of Clinical Oncology, vol. 25, supplement 18S, abstract no. 11072, 2007. View at Google Scholar
  12. L. Hajra, J. Fralick, J. Sue et al., “Trastuzumab-mediated cardiotoxicity in the non trial setting: Evaluation of patient receiving adjuvant trastuzumab at an academic cancer centre,” in Proceedings of the ASCO Breast Cancer Symposium, 2007, abstract no 241.
  13. J. R. Mackey, M. Clemons, M. A. Côté et al., “Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group,” Current Oncology, vol. 15, no. 1, pp. 24–35, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. E. H. Romond, E. A. Perez, J. Bryant et al., “Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer,” The New England Journal of Medicine, vol. 353, pp. 1673–1684, 2005. View at Google Scholar